Evidence map›Paper›PMID 39350339›Full record

ArticleBriefings in bioinformatics2024

scPanel: a tool for automatic identification of sparse gene panels for generalizable patient classification using scRNA-seq datasets.

Yi Xie, Jianfei Yang, John F Ouyang, Enrico Petretto

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yi XieProgramme in Cardiovascular and Metabolic Disorders, Centre for Computational Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.ORCID 0000-0002-1938-4089
Jianfei YangThe School of Mechanical and Aerospace Engineering and the School of Electrical and Electronic Engineering, Nanyang Technological University, 50 Nanyang Ave, Singapore 639798, Singapore.ORCID 0000-0002-8075-0439
John F OuyangProgramme in Cardiovascular and Metabolic Disorders, Centre for Computational Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.ORCID 0000-0002-1239-1577
Enrico PetrettoProgramme in Cardiovascular and Metabolic Disorders, Centre for Computational Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.ORCID 0000-0003-2163-5921

Funding

Enrico Petretto and Singapore National Medical Research Council MOH-OFYIRG21nov-0004Singapore Ministry of Education MOE-T2EP30221-0007Singapore National Medical Research Council MOH-OFLCG22may-0003
6 · The paper itself

Abstract

Single-cell RNA sequencing (scRNA-seq) technologies can generate transcriptomic profiles at a single-cell resolution in large patient cohorts, facilitating discovery of gene and cellular biomarkers for disease. Yet, when the number of biomarker genes is large, the translation to clinical applications is challenging due to prohibitive sequencing costs. Here, we introduce scPanel, a computational framework designed to bridge the gap between biomarker discovery and clinical application by identifying a sparse gene panel for patient classification from the cell population(s) most responsive to perturbations (e.g. diseases/drugs). scPanel incorporates a data-driven way to automatically determine a minimal number of informative biomarker genes. Patient-level classification is achieved by aggregating the prediction probabilities of cells associated with a patient using the area under the curve score. Application of scPanel to scleroderma, colorectal cancer, and COVID-19 datasets resulted in high patient classification accuracy using only a small number of genes (<20), automatically selected from the entire transcriptome. In the COVID-19 case study, we demonstrated cross-dataset generalizability in predicting disease state in an external patient cohort. scPanel outperforms other state-of-the-art gene selection methods for patient classification and can be used to identify parsimonious sets of reliable biomarker candidates for clinical translation.

Indexed as

COVID-19Single-Cell AnalysisColorectal NeoplasmsComputational BiologyGene Expression ProfilingHumansRNA-SeqSARS-CoV-2Sequence Analysis, RNASingle-Cell Gene Expression AnalysisSoftwareTranscriptomeclinical biomarkersdeep learningmachine learningmarker panelpatient classificationsingle-cell RNA-seq

Identifiers

PMID39350339
PMCPMC11442147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.